Australia's most trusted
source of pharma news
Saturday, 15 March 2025
Posted 13 March 2025 PM
Astellas has carved out an earlier prostate cancer treatment setting for Xtandi as generics circle the company’s top earning drug in Australia.
Last month, the TGA approved the androgen receptor pathway inhibitor (ARPI) for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence at high-risk for metastasis (high-risk BCR), marking the first and only ARPI approved for the indication in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.